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ACIP Hepatitis WG Terms of Reference
 Hepatitis A
• Update hepatitis A recommendations (2006)
– Prevention of hepatitis A through active or passive 
immunization: recommendations of the Advisory Committee on 
Immunization Practices (ACIP), MMWR, May 19, 2006, Vol 55, 
#RR-07 
22
Current Recommendations Published Since 2006
 Updated Recommendations from the ACIP for Use of Hepatitis A Vaccine in Close 
Contacts of Newly Arriving International Adoptees, MMWR, September 18, 2009, 
Vol 58, #36 
 Updated Recommendations from the ACIP for Use of Hepatitis A Vaccine for 
Postexposure Prophylaxis and for Preexposure Prophylaxis for International Travel,  
MMWR, November 2, 2018, Vol 67, #43 
 Recommendations of the Advisory Committee on Immunization Practices for Use 
of Hepatitis A Vaccine for Persons Experiencing Homelessness, MMWR, February 
15, 2019, Vol 68, #6 
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Work Group Considerations 
 May 2014 - June 2019
–
–
Thirty-one meetings focused on hepatitis A vaccine topics
 March 2019 - June 2019
Five meetings focused on the proposed updated hepatitis A 
vaccine statement
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Today’s Session – I
 Hepatitis A vaccines – 3 votes
– (1) Hepatitis A catch-up vaccination
• Hepatitis A vaccines have demonstrated safety and efficacy for over 20 years
• Nearly the entire cohort of children aged 13-17 years assessed in 2017, living in states 
where vaccination was recommended in 2006, were not yet subject to the routine 
recommendation for childhood vaccination
– Yet as of 2017, more than 3 out of 4 teens had initiated the series and over 2/3 
were fully vaccinated
• 40% of states have a daycare or school mandate, or both, for HepA vaccination in 2018, 
increasing over time from hepatitis A vaccine introduction
• 27 of 30 state immunization information systems (IIS) already routinely forecast 
hepatitis A vaccine as being due for an 18 year old who has never been vaccinated 
(American Immunization Registry Association)
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Today’s Session - II
 Hepatitis A vaccines – 3 votes
–
–
(2) HIV as a risk group for increased HAV infection severity
• When persons with HIV (PWHIV) are co-infected with hepatitis A virus (HAV) infection, they 
experience higher peak HAV viral loads and a prolonged duration of hepatitis A viremia than 
persons without HIV infection
• PWHIV usually respond to hepatitis A vaccination, particularly when the CD4 cell count is 
>200 cells/mm3 and the PWHIV has a low HIV RNA viral load  
• HIV co-infection outbreak data is available for a limited number of outbreak associated 
states, indicating excess risk of PWHIV to HAV infection in those states
• Data from the medical monitoring project also indicates substantial HAV infection among 
PWHIV
(3) Full updated hepatitis A vaccine statement
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Next Steps
 Continue deliberations on adult hepatitis B vaccination topics
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